Overexpression and knockout of miR-126 both promote leukemogenesis

Blood

Volumn 126, Issue 17, 2015, Pages 2005-2015

  Li, Zejuan ^a,j   Chen, Ping ^a   Su, Rui ^b   Li, Yuanyuan ^a   Hu, Chao ^a,b,c   Wang, Yungui ^a,b,c   Arnovitz, Stephen ^a   He, Miao ^a,d   Gurbuxani, Sandeep ^e   Zuo, Zhixiang ^a,b   Elkahloun, Abdel G ^f   Li, Shenglai ^a   Weng, Hengyou ^a,b   Huang, Hao ^a   Neilly, Mary Beth ^a   Wang, Shusheng ^g,h   Olson, Eric N ^g   Larson, Richard A ^a   Le Beau, Michelle M ^a   Zhang, Jiwang ⁱ   Jiang, Xi ^a,b   Wei, Minjie ^d   Jin, Jie ^c   Liu, Paul P ^f   Chen, Jianjun ^a,b   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF CHICAGO   (United States)

^f NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h Tulane University   (United States)

ⁱ LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 126; ANTINEOPLASTIC AGENT; MICRORNA; MIRN126 MICRORNA, HUMAN; MIRN126 MICRORNA, MOUSE; ONCOPROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMOGENESIS; LONG TERM SURVIVAL; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CANCER STAGING; CELL DIFFERENTIATION; CELL TRANSFORMATION; CHROMOSOME 21; CHROMOSOME 8; FEMALE; GENE TRANSLOCATION; GENETICS; KNOCKOUT MOUSE; LEUKEMIA, MYELOID, ACUTE; MALE; MORTALITY; MOUSE; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; SURVIVAL RATE; TRANSLOCATION, GENETIC;

EID: 84944884379     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-04-639062     Document Type: Article

References (65)

1. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.
2. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130-1134.
3. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828-833.
4. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer. 2010;10(1):23-36.
5. Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147-152.
6. Jiang X, Huang H, Li Z, et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 2012;22(4):524-535.
7. Korpal M, Ell BJ, Buffa FM, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 2011;17(9):1101-1108.
8. Ell B, Mercatali L, Ibrahim T, et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 2013;24(4):542-556.
9. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261-271.
10. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15(2):272-284.
11. ∗ against metastasis. Nat Cell Biol. 2013;15(3):231-233.
12. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2011;481(7380):190-194.
13. ∗ repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013;15(3):284-294.
14. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009;66(2):169-175.
15. Li N, Tang A, Huang S, et al. MiR-126 suppresses colon cancer cell proliferation and invasion via inhibiting RhoA/ROCK signaling pathway. Mol Cell Biochem. 2013;380(1-2):107-119.
16. Jia AY, Castillo-Martin M, Bonal DM, Sánchez-Carbayo M, Silva JM, Cordon-Cardo C. MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. Br J Cancer. 2014;110(12):2945-2954.
17. Tai HC, Chang AC, Yu HJ, et al. Osteoblastderived WNT-induced secreted protein 1 increases VCAM-1 expression and enhances prostate cancer metastasis by down-regulating miR-126. Oncotarget. 2014;5(17):7589-7598.
18. Chen H, Li L, Wang S, et al. Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. Oncotarget. 2014;5(23):11873-11885.
19. Sasahira T, Kurihara M, Bhawal UK, et al. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer. 2012;107(4):700-706.
20. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA. 2008;105(40):15535-15540.
21. Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int J Hematol. 2011;94(2):126-133.
22. Link KA, Chou FS, Mulloy JC. Core binding factor at the crossroads: determining the fate of the HSC. J Cell Physiol. 2010;222(1):50-56.
23. Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest. 2000;18(8):768-780.
24. de Leeuw DC, Denkers F, Olthof MC, et al. Attenuation of microRNA-126 expression that drives CD34+38-stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res. 2014;74(7):2094-2105.
25. Dorrance AM, Neviani P, Ferenchak GJ, et al. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia [published online ahead of print August 21, 2015]. Leukemia. 2015.
26. Lechman ER, Gentner B, van Galen P, et al. Attenuation of miR-126 activity expands HSC in vivo without exhaustion. Cell Stem Cell. 2012;11(6):799-811.
27. Gaiano N, Kohtz JD, Turnbull DH, Fishell G. A method for rapid gain-of-function studies in the mouse embryonic nervous system. Nat Neurosci. 1999;2(9):812-819.
28. Pritsker M, Ford NR, Jenq HT, Lemischka IR. Genomewide gain-of-function genetic screen identifies functionally active genes in mouse embryonic stem cells. Proc Natl Acad Sci USA. 2006;103(18):6946-6951.
29. Barton MK, Schedl TB, Kimble J. Gain-of-function mutations of fem-3, a sex-determination gene in Caenorhabditis elegans. Genetics. 1987;115(1):107-119.
30. Strachan T, Read AP. Human Molecular Genetics. 2nd ed. New York: Wiley-Liss; 1999.
31. Mohamed AM, Chin-Sang ID. Characterization of loss-of-function and gain-of-function Eph receptor tyrosine kinase signaling in C. elegans axon targeting and cell migration. Dev Biol. 2006;290(1):164-176.
32. Li Z, Huang H, Chen P, et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun. 2012;3:688.
33. Huang H, Jiang X, Li Z, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 2013;110(29):11994-11999.
34. Li Z, Huang H, Li Y, et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012;119(10):2314-2324.
35. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1-2):70-78.
36. Zuber J, Radtke I, Pardee TS, et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009;23(7):877-889.
37. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
38. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27-30.
39. Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t (8;21) transcript promotes leukemogenesis. Nat Med. 2006;12(8):945-949.
40. Ahn EY, Yan M, Malakhova OA, et al. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis. Proc Natl Acad Sci USA. 2008;105(44):17103-17108.
41. Wang YY, Zhao LJ, Wu CF, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA. 2011;108(6):2450-2455.
42. Mrózek K, Marcucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol. 2008;20(6):711-718.
43. Peterson LF, Boyapati A, Ahn EY, et al. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t (8;21) transcripts. Blood. 2007;110(3):799-805.
44. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593-5603.
45. Schessl C, Rawat VP, Cusan M, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest. 2005;115(8):2159-2168.
46. Jiao B, Wu CF, Liang Y, et al. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t (8;21) acute myeloid leukemia-M2. Leukemia. 2009;23(9):1598-1604.
47. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98(9):5116-5121.
48. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010;304(24):2706-2715.
49. Ferby I, Reschke M, Kudlacek O, et al. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med. 2006;12(5):568-573.
50. Descot A, Hoffmann R, Shaposhnikov D, Reschke M, Ullrich A, Posern G. Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction. Mol Cell. 2009;35(3):291-304.
51. Zhang YW, Staal B, Su Y, et al. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene. 2007;26(2):269-276.
52. Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007;39(9):1120-1126.
53. Yoshida T, Hisamoto T, Akiba J, et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene. 2006;25(45):6056-6066.
54. Pasmant E, Ballerini P, Lapillonne H, et al. SPRED1 disorder and predisposition to leukemia in children [letter]. Blood. 2009;114(5):1131.
55. Pasmant E, Gilbert-Dussardier B, Petit A, et al. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. Oncogene. 2015;34(5):631-638.
56. Chakrabarti R, Wei Y, Hwang J, et al. ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol. 2014;16(10):1004-1015.
57. Fernandez A, Huggins IJ, Perna L, et al. The WNT receptor FZD7 is required for maintenance of the pluripotent state in human embryonic stem cells. Proc Natl Acad Sci USA. 2014;111(4):1409-1414.
58. Flanagan DJ, Phesse TJ, Barker N, et al. Frizzled7 functions as a Wnt receptor in intestinal epithelial Lgr5 (1) stem cells. Stem Cell Rep. 2015;4(5):759-767.
59. Boissel N, Leroy H, Brethon B, et al; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965-970.
60. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121(5):775-777.
61. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791-1799.
62. Paschka P, Marcucci G, Ruppert AS, et al; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t (8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911.
63. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 2004;23(43):7178-7187.
64. Bloomfield CD, Ruppert AS, Mrózek K, et al; Cancer and Leukemia Group B (CALGB) Study 8461. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Ann Hematol. 2004;83(Suppl 1):S84-S85.
65. Byrd JC, Ruppert AS, Mrózek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv (16) (p13q22) or t (16;16) (p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22(6):1087-1094.